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Abstract
Medulloblastoma is the most common pediatric posterior fossa malignancy, with a 5-year overall survival of only
60% and many survivors experiencing treatment-related morbidity secondary to current therapeutic regimens. With
an improved understanding of the molecular basis for this disease, the opportunity to develop novel treatments with
more tolerable toxicity profiles that target key molecular pathways, now exists. Recently, the hepatocyte growth fac-
tor (HGF)/MET signaling pathway has been implicated in medulloblastoma pathogenesis. Several therapeutic strate-
gies targeting this pathway exist, including small molecule inhibitor therapy against the MET receptor tyrosine
kinase. We examined the in vitro efficacy of targeting the MET receptor using the highly specific small molecule
inhibitor PHA665752 as a novel treatment strategy in medulloblastoma. MET inhibition using PHA665752 was effec-
tive at reducing the proliferative capacity of the D283, ONS76, and MED8A medulloblastoma cell lines as assessed
by MTS assay. Furthermore, PHA665752 treatment reduced D283 and ONS76 cell motility and impaired the growth
of D283 cells in soft agar. Pretreatment of D283, ONS76, and MED8A cells with PHA665752 blocked exogenous
recombinant human HGF-induced up-regulation of the downstream RAS/mitogen-activated protein kinase signaling
pathway in D283, ONS76 and MED8A cell lines. Similarly, PHA665752 prevented HGF-induced phosphatidylinositol
3-kinase/AKT signaling in ONS76 and MED8A cells. These results highlight the efficacy of targeting the MET receptor
tyrosine kinase therapeutically in medulloblastoma and provide support for further preclinical testing of small mole-
cule inhibitors targeting the MET receptor in medulloblastoma.
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Introduction
Medulloblastoma (MB) is the most common malignant pediatric pos-
terior fossa brain tumor, affecting young children with a peak incidence
at 7 years [1–3]. Current therapy involves a combination of surgery, ra-
diation, and conventional chemotherapeutic strategies—therapies with
significant inherent risks of neurocognitive, endocrinologic, hemato-
logic, and oncologic adverse effects [4–7]. Furthermore, current 5-year
survival rates are approximately 60% despite aggressive therapy. An in-
creased understanding of the molecular pathogenesis of this tumor has
offered the promise of therapeutic strategies with improved toxicity pro-
files, targeting key signaling pathways implicated in MB formation or
progression. The hepatocyte growth factor (HGF)/MET signaling
pathway has been implicated in the pathogenesis of a variety of human
malignancies including MB, and it represents a novel therapeutic target
in this disease [8–13]. Several strategies aimed at limiting HGF/MET
signaling are available, including ATP-competitive small molecule in-
hibitors of the MET receptor tyrosine kinase [14]. The use of small
molecule MET inhibition has been evaluated in other human malig-
nancies such as neuroblastoma; however, it has yet to be reported as
a therapeutic strategy in MB [13]. Here, we have examined the in vitro
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efficacy of the MET-selective small molecule inhibitor PHA665752
(Pfizer, La Jolla, CA) against human MB.
Several strategies to blockHGF/METsignaling have been explored, in-
cluding interfering with ligand-receptor interaction, inhibition of MET
tyrosine kinase activity, and disruption of MET interaction with down-
stream effector molecules [15]. Antagonism of the ligand-receptor inter-
actionmay be effective in tumors whereMETsignaling is driven in either
a paracrine or an autocrine manner by HGF ligand. Strategies to block
ligand-receptor binding have included the use of truncated or uncleavable
HGF (NK2 [N-terminal hairpin, first two Kringle domains], NK4 [N-
terminal hairpin, first four Kringle domains], uncleavable pro-HGF),
neutralizing antibodies against HGF or the MET receptor, and decoy
METreceptors [16–24]. DecoyMETreceptors also interfere with endog-
enous METreceptor dimerization and subsequent downstream signaling
[14]. With respect to MB specifically, preclinical evidence demonstrating
efficacy of the HGF-neutralizing monoclonal antibody L2G7 at improv-
ing the survival of mice with MBs induced by a combination of Sonic
Hedgehog (SHH) and HGF compared with control antibody therapy
exists [8,17]. METsignaling can be upregulated in a ligand-independent
fashion through wild-type receptor overexpression or through activating
translocation or mutation events. In such cases, strategies targeting the
METreceptor may directly prove to be more efficacious.
One method of inhibiting METreceptor tyrosine kinase activity is to
use small molecule inhibitor therapy. The effectiveness of small molecule
inhibitor therapies has been demonstrated by the clinical success
achieved with agents such as Gleevec for chronic myelogenous leukemia
and gastrointestinal stromal tumors, Herceptin for human epidermal
growth factor receptor 2–positive breast cancer, and Iressa for non–small
cell lung cancer [25]. A small molecule inhibitor targeting the SHH
pathway (HhAntag) has shown effectiveness in preclinical Patched-
deficient murine models of MB [26]. Several small molecule inhibitors
targeting the MET kinase have been developed, but their efficacy inMB
has yet to be reported [27,28].
We have examined the effectiveness ofMETkinase inhibition in vitro
inMB using the small molecule inhibitor PHA665752. PHA665752 is
an ATP-competitive small molecule inhibitor, which exhibits more than
50-fold selectivity for MET compared with other tyrosine and serine-
threonine kinases [29]. It has been shown to inhibit MET-dependent
functions including cell proliferation, migration, and branching mor-
phogenesis. In cells that lack METexpression, PHA665752 treatment
at concentrations of up to 18 μM has no biologic effect [29]. Its effec-
tiveness has been demonstrated in animal xenograft models of small cell
and non–small cell lung cancers, in which PHA665752 treatment re-
duced xenograft size and impaired tumor angiogenesis [30]. In a model
of esophageal adenocarcinoma, PHA665752 treatment reduced cell via-
bility and cell motility [31]. In this model, PHA665752 treatment was
associated with reduced downstreamMET-mediated mitogen-activated
protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) path-
way activation [31]. In the current study, we show that anti-METsmall
molecule inhibitor therapy represents a novel targeted treatment strategy
that warrants further investigation in preclinical models.
Materials and Methods
Cell Lines, Cell Culture, and PHA665752 Treatment
D283 MB cells were obtained from the American Type Culture
Collection (ATCC, Rockland, MD). The ONS76 MB cell line was
obtained from the Institute for Fermentation (Osaka, Japan). The
MED8A MB cell line was obtained from Dr. R. Gilbertson (St Jude
Children’s Research Hospital, Memphis, TN). The D283 cell line was
initially isolated from a patient withmetastaticMB [32].ONS76 cell line
was isolated from a MB from a 2-year-old girl [33]. MED8A was iso-
lated from a patient younger than 2 years at the time of diagnosis [34].
Taken together, all three cell lines are from high-risk invasiveMB disease.
D283 and ONS76 were maintained in culture in Dulbecco modi-
fied Eagle medium (DMEM) supplemented with 10% FBS and 1×
antibiotic/antimycotic solution. MED8Awas cultured in DMEM sup-
plemented with 20% FBS and 1× antibiotic/antimycotic solution. All
cell lines were kept at 37°C, in 5% CO2. Media and reagents for cell
culture were purchased fromWisent, Inc (St Bruno, Quebec, Canada).
The small molecule MET inhibitor PHA665752 was purchased from
Tocris Bioscience (Ellisville, MO).
MTS Cell Proliferation Assay
The Promega CellTiter 96 AQueous One Solution Cell Prolifera-
tion Assay was used, as per the manufacturer’s instructions (Promega,
Madison, WI). Cells were seeded into 96-well plates (1000 cells/well)
in triplicate. Absorbance at 490 nm was measured 2 hours after the ad-
dition of 20 μl of MTS reagent/well, every 24 hours during a 96-hour
period. PHA665752 or DMSO (vehicle control) was added to the
media in respective wells at the time of cell plating. The cells were in-
cubated in the presence of the inhibitor for the entire course of the
experiment; however, the medium was not changed or supplemented
with additional inhibitor.
Detection of Apoptosis through Production of
Cleaved Caspase-3
A cleaved caspase-3 assay was performedwith untreated cells andwith
cells treatedwith 2.5 μMPHA665752 for 12, 24, 36, or 48 hours. After
treatment, cell lysates were prepared, andWestern blot analysis was per-
formed. Full-length intact caspase-3 or the cleaved caspase-3 product
indicative of apoptosis pathway activation was detected with caspase-3
antibody (1:1000; Cell Signaling Technology, Beverly, MA). Jurkat cells
untreated or treated with cytochrome c serve as negative and positive
lysate controls, respectively (Cell Signaling Technology).
Artificial Wound Healing Assay
An artificial wound healing assay was performed to assess cells’migra-
tory ability. Cell lines were grown to confluence in a medium contain-
ing 10% FBS, in triplicate in six-well plates. A uniform scratch defect
(“wound”) was created across themonolayer using a p10 pipette tip.Wells
were then washed with 1× phosphate-buffered saline, followed by the ad-
dition of serum-free medium containing either 2 μM PHA665752 or
DMSO control. Plates were imaged immediately (T = 0 hour) and at
18 hours (T = 18 hours), and the degree to which cells at the wound
margin had migrated in to close the initial defect was assessed.
Colony Formation in Soft Agar Assay
A base layer of 1.5% agar/2× DMEM/FBS was prepared in 35-mm
plates. The upper-layer agar was made using 1.5% agar, 2× DMEM,
FBS, and sterile water and was kept in the liquid phase in a 42°C water
bath. Cells were resuspended in 0.75% agar/DMEM/FBS and overlaid
on the base layer with 1000 cells/35-mm plate. PHA665752 or DMSO
was added to both base- and upper-layer agars before plating. Once the
agar had solidified, plates were overlaid with phosphate-buffered saline
containing either PHA665752 or DMSO of the same concentration as
in the agar layers. Plates were kept in a humidified chamber at 37°C
for 2 weeks, stained with crystal violet, and digitally imaged. Each
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cell line was plated in triplicate, and the data presented are representa-
tive of three separate experiments. Of the MB cell lines examined, only
the D283 line grew readily under anchorage-independent conditions
at baseline.
Western Blot Analysis
MB cell lines were cultured overnight in serum-free DMEM. Cells
were then pretreated with either 2 μMPHA665752 or DMSO control
for 3 hours, followed by the addition of 20 ng/ml of recombinant
human HGF (Sigma-Aldrich, St Louis, MO) for 20 minutes before
obtaining protein cell lysates with radioimmunoprecipitation assay
buffer. Primary antibodies were used at a 1:1000 dilution, hybridized
overnight at 4°C. Anti-AKT and anti–p-AKT antibodies were pur-
chased from Cell Signaling Technology. Anti-ERK1/2 (extracellular
regulated kinase 1/2) and anti–p-ERK1/2 antibodies were purchased
from Santa Cruz Biotechnology.
Results
PHA665752-Mediated MET Inhibition Reduces MB Cell
Proliferation In Vitro
Given that HGF/MET signaling activates downstream mitogenic
effectors, we examined the effect of PHA665752 treatment on MB
cell proliferation by MTS assay. The D283 MB cell line showed a
dose-response effect with greater reduction in proliferative capacity as
assessed by MTS assay during a 96-hour period with increasing doses
of PHA665752 (range = 1.0-2.0 μM) compared with untreated or vehi-
cle control (DMSO)–treated cells (Figure 1A). PHA665752 doses be-
tween 1.5 and 2.0 μM were particularly effective at limiting D283 cell
growth. Similarly, both ONS76 and MED8A MB cells exhibited a
dose-response effect of reduced cell proliferation in response to increas-
ing dose of PHA665752 (range = 1.5-2.5 μM; Figure 1, B and C). The
ONS76 cell line was sensitive to MET inhibition by PHA665752,
with doses between 1.75 and 2.5 μM reducing cell proliferation (Fig-
ure 1B). In fact, ONS76 cells failed to proliferate when treated with doses
greater than 2.0 μM.MED8A cells were sensitive to PHA665752 doses
of 1.5 μM and greater and failed to proliferate in doses greater than
2.0 μM (Figure 1C).
It is possible that the PHA665752 is meditating its effect by activat-
ing apoptosis in the treated MB cells. Therefore, we checked for acti-
vation of the apoptotic pathway by Western blot analysis for cleaved
caspase-3 in lysates from untreated or treated D283 or ONS76 cells.
We observed no cleavage of the intact caspase-3 protein and no de-
tection of the cleaved caspase-3 product that is indicative of apoptotic
pathway activation (Figure W1).
PHA665752-Mediated MET Inhibition Reduces MB Cell
Migration In Vitro
HGF/MET signaling is known to promote cell motility. The effect
of MET inhibition on MB cell motility was assessed using an artificial
wound healing assay. MET inhibition by PHA665752 reduced D283
MB cell motility in comparison to DMSO-treated controls, as evi-
denced by the impaired closure of an artificial wound at 18 hours after
creation of the defect in a confluent D283 cell monolayer (Figure 2A).
Similarly, ONS76 cells migrated more slowly with PHA665752 treat-
ment, demonstrating complete closure of the defect at 18 hours in
control-treated cells but persistence of a visible defect in the cell mono-
layer for PHA665752-treated cells (Figure 2B). The MED8A cell line
was excluded from this experiment because there was a significant loss
of cell adherence when plated in serum-free conditions when setting up
the wound healing assay.
PHA665752-Mediated MET Inhibition Abrogates D283
Cell Capacity for Anchorage-Independent Growth
One key characteristic of transformed cells is the acquisition of the
capability to proliferate in an anchorage-independent manner. We tested
the effects of MET inhibition onMB cell capacity to evade anoikis using
a colony formation assay in soft agar. Of the three MB cell lines ex-
amined, D283 MB cells possess the capacity to form colonies readily
under conditions of anchorage-independent growth. When grown
under anchorage-independent conditions, D283 MB cells treated with
DMSO alone readily form macroscopically visible colonies after 2 weeks
in culture (Figure 3). In comparison, when grown under similar condi-
tions but in the presence of 1.5 μM PHA665752, macroscopic colonies
fail to form (Figure 3). The experiment was repeated three times, and
enumerated colonies between dose conditions were evaluated for sta-
tistical significance. Treatment with 1.5, 1.75, and 2 μM PHA665752
was determined to be statistically different compared with untreated
(P = .0021).
PHA665752-Mediated MET Inhibition Blocks
HGF-Induced Downstream Signaling through the
MAPK and PI3K Pathways
Given the effects of PHA665752 onMB cell proliferation, migration,
and anchorage-independent growth, we examined the consequences of
MET inhibition on downstream signaling molecules in the HGF/
MET pathway. Stimulation of serum-starved D283 cells with exoge-
nous HGF resulted in increased signaling through the MAPK pathway,
as evidenced by increased phosphorylated ERK1/2 (Figure 4A). Pretreat-
ment of D283 cells with PHA665752 completely abrogated this HGF-
induced ERK1/2 phosphorylation. In contrast, serum-starved D283
cells maintained active PI3K signaling as evidenced by high levels of
AKT phosphorylation (Figure 4B). This was not demonstrably altered
by exogenous HGF treatment or PHA665752 treatment, which indi-
cates that, in the D283 cell line, the PI3K/AKT pathway is activated
by an alternate mechanism or upstream molecule. In addition, this in-
dicates that the PHA665752 inhibitor is not acting in a nonspecific
manner given the inability to attenuate AKT activation in this cell line.
Serum-starved ONS76 cells exhibited low levels of basal MAPK and
PI3K signaling, both of which were upregulated after exogenous HGF
stimulation, as seen by increased phospho-ERK1/2 and phospho-AKT
levels, respectively (Figure 4, C and D). Pretreatment of ONS76 cells
with PHA665752 maintained phospho-ERK1/2 and phospho-AKT
levels at their basal levels despite HGF stimulation. Serum-starved
MED8A cells stimulated with exogenous HGF demonstrated increased
MAPK and PI3K signaling, as seen by increased phospho-ERK1/2
and phospho-AKT, respectively (Figure 4, E and F ). Pretreatment of
MED8A cells with PHA665752 completely blocked this HGF-induced
up-regulation in MAPK and PI3K signaling.
Discussion
We observed a reproducible dose-response effect of PHA665752 treat-
ment on reducing cell proliferation in vitro, across several MB cell
lines examined (Figure 1). With increasing dose of PHA665752,
D283 cells showed progressive impairment of cell proliferation as mea-
sured by the MTS assay (Figure 1A). ONS76 and MED8A cell lines
also demonstrated a dose-response reduction in proliferative capacity
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Figure 1.MTS proliferation assay for D283 MB cells (A), ONS76 MB cells (B), and MED8A MB cells (C) treated with an increasing dosage
of PHA665752, in comparison to untreated cells and DMSO vehicle control–treated cells. A dose-response effect was observed for each
cell line, with an increasing dosage of PHA665752 resulting in a greater reduction in cell proliferation during the 96-hour culture.
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in response to PHA665752-mediatedMET inhibition (Figure 1, B and
C ). PHA665752 treatment was also effective at limiting MB cell mo-
tility as determined by an artificial wound healing assay (Figure 2).
PHA665752 treatment impaired MB cell capacity for anchorage-
independent growth, with no colonies visible after 2 weeks of growth
in soft agar (Figure 3). At the molecular level, MET signaling results
in upregulated downstream MAPK kinase signaling in the D283,
ONS76, and MED8A cell lines and in upregulated PI3K signaling
Figure 2. Artificial wound healing assay. (A) D283 cells treated with DMSO-vehicle control (D283–control) alone demonstrate near-
complete closure of the initial defect in the cell monolayer (T = 0 hour) after 18 hours in culture (T = 18 hours). In contrast, D283 cells
treated with the MET inhibitor PHA665752 (D283–PHA665752) demonstrate reduced migratory ability, with the initial defect (T = 0 hour)
closed by only approximately 50% after 18 hours in culture (T = 18 hours). (B) ONS76 cells treated with DMSO-vehicle control alone
(ONS76–control) demonstrate complete closure of the monolayer defect after 18 hours in culture, whereas this closure remains incom-
plete with PHA665752 treatment (ONS76–PHA665752).
Figure 3. Colony formation in soft agar assay. D283 cells grown under anchorage-independent conditions in soft agar readily form macro-
scopically visible colonies when treated with DMSO–vehicle control alone (D283–DMSO). Visible colonies fail to form after PHA665752
treatment (D283–PHA665752 1.5 μM). Images are of 35-mm culture plates after 2 weeks’ duration in culture.
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in the ONS76 and MED8A cell lines (Figure 4). Pretreatment of these
cell lines with PHA665752 before stimulation using exogenous HGF
reduces phospho-ERK1/2 levels back to baseline levels in all three cell
lines and reduces phospho-AKT levels in the ONS76 and MED8A cell
lines (Figure 4).
TheHGF/METpathway is known to play a crucial role in diverse pro-
cesses including normal development and tissue homeostasis. Dysregu-
lation of HGF/MET signaling has been implicated in several human
malignancies, including gastrointestinal, bladder, breast, ovarian, renal,
hepatocellular, lung, prostate, and central nervous system tumors [15].
Activation of the MET receptor tyrosine kinase normally results from
binding by its ligand, HGF [35,36]. On binding of HGF, METunder-
goes autophosphorylation and recruits intracellular adapters that me-
diate diverse downstream biologic effects through multiple signaling
pathways including the RAS/MAPK and PI3K/AKTsignaling pathways
[15]. In cancer, excess HGF/MET signaling may be secondary to loss
of normal pathway inhibition, HGF ligand overexpression (with resul-
tant auto or paracrine pathway activation), MET gene amplification
or overexpression, MET gene rearrangements, or activating mutations
[14,15]. Pathway activation promotes mitogenesis, morphogenesis, cell
Figure 4. (A) Treatment of serum-starved D283 cells with exogenous recombinant human HGF (rhHGF) stimulates downstream MAPK sig-
naling, as shown by an increase in phospho-ERK1/2. Pretreatment with PHA665752 abrogates this HGF-mediated increase in phospho-
ERK1/2. (B) Treatment of serum-starved D283 cells with rhHGF does not alter PI3K activity, as evidenced by high levels of phospho-AKT with
or without rhHGF treatment. PHA665752 treatment also does not alter phospho-AKT levels in the D283 cell line. (C) Treatment of serum-
starved ONS76 cells with rhHGF results in increased phospho-ERK1/2. Pretreatment with PHA665752 reduces phospho-ERK1/2 levels to
baseline. (D) Similarly, rhHGF increased phospho-AKT levels in ONS76 cells, with PHA665752 pretreatment reducing phospho-AKT levels
to baseline. (E) Treatment of serum-starved MED8A cells with rhHGF results in increased phospho-ERK1/2. Pretreatment with PHA665752
reduces phospho-ERK1/2 levels to baseline. (F) Similarly, rhHGF treatment increases phospho-AKT levels in MED8A cells, with PHA665752
pretreatment reducing phospho-AKT levels to baseline.
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motility, angiogenesis, and resistance to anoikis-induced apoptosis—a
coordinated biologic program called invasive growth [14,15,37]. While
in the normal context, this program of MET signaling–mediated inva-
sive growth is crucial for tissue and organ morphogenesis; in the context
of cancer, it may contribute to tumorigenesis, disease progression, and
metastasis [38].
The role of HGF/MET signaling in cerebellar development has
been well established [39]. The MET-mediated pattern of invasive
growth may be exemplified by the normal proliferation, migration,
and invasion of normal cerebellar external granule cell precursors (GCPs;
suspectedMB cell of origin), as they proliferate and then undergomigra-
tion and invade into in the developing cerebellum to form the mature
internal granule cell layer. Murine cerebellar GCPs express MET and
proliferate in response to HGF [39]. HGF and MET are expressed in
the human fetal and adult cerebella [40,41]. In vitro HGF treatment
of GCPs prevents apoptotic cell death [42]. Lastly, mice harboring a
hypomorphic mutant form of Met, in which Met signaling capacity is
reduced, display a reduction in overall cerebellar size with foliation de-
fects in the central and posterior vermis [39].
Dysregulation of normal developmental signaling pathways, such as
Hedgehog andWNTsignaling, has been implicated in the pathogenesis
of MB. Aberrant MET signaling beyond the developmental period,
during which it is required for proper external granule layer cell migra-
tion and establishment of the internal granule layer, may contribute to
MB pathogenesis by promoting cell proliferation and inhibiting apop-
tosis and toMBmetastasis through its ability to promote cell migration,
invasion, and resistance to anoikis-induced apoptosis.
MET amplifications have been identified in 38.5% of primary
human MB samples by comparative genomic hybridization [43]. In
addition, several established MB cell lines and primary patient sam-
ples express high levels of HGF and MET proteins [11]. Loss of nor-
mal pathway inhibition has also been implicated in aberrant HGF/
METsignaling in MB [9]. Furthermore, highMET receptor messenger
RNA expression in primary patient samples correlates with reduced
overall survival [11]. Experimentally, exogenous HGF treatment of
MB cell lines results in downstream phosphorylation of both MAPK
and AKT [11]. Exogenous HGF increases cell proliferation, anchorage-
independent growth, and cell cycle progression and reduces apoptosis in
response to chemotherapy [11]. In vivo, HGF overexpression enhances
MB xenograft tumor formation in an immunodeficient mouse model
[11]. HGF/MET pathway inhibition limits the growth of intracerebellar
MB xenografts [9]. Overexpression of HGF in murine GCPs in con-
junction with SHH increases de novoMB formation in comparison with
SHH alone [8]. As such, the HGF/MET pathway may represent an
effective target for novel therapeutic strategies in MB.
We have demonstrated for the first time that targeting theMETrecep-
tor tyrosine kinase using small molecule inhibitor therapy is effective
against MB in vitro at reducing cell proliferation, migration, and growth
under anchorage-independent conditions. The exact mechanism of how
the PHA665752 exerts its dramatic effect on MB cells remains to be
determined. Our studies indicate that it is not likely due to the activa-
tion of the apoptotic pathway; therefore, it is likely an effect mediated on
the cell cycle. The biologic consequences of MET inhibition by
PHA665752 may be in part due to inhibition of key downstream onco-
genic signaling pathways, including the RAS/MAPK and PI3K/AKT
pathways. Of interest was the lack of inhibition of the PI3K/AKT path-
way in the D283 cell line, suggesting this pathway is activated by a
c-Met–independent signaling event. It is possible that this represents a
MB subtype variant and may be of importance when profiling potential
candidates for therapeutic responsiveness to this inhibitor. As a proof-of-
principle study to determine the utility of targeting the MET kinase in
MB, these data demonstrating the effectiveness of PHA665752 in vitro
are informative, owing to the high selectivity of this agent for the MET
receptor in comparison to other commercially available agents [14,29].
To date, however, the clinical application of PHA665752 has been hin-
dered because of poor pharmacokinetics and low oral bioavailability [14].
With the knowledge that specific targeting of the METreceptor tyrosine
kinase in MB limits the malignant phenotype in vitro, future studies us-
ing preclinical models of MB to investigate new small molecule MET
inhibitors with improved kinetics are warranted.
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Figure W1. D283 cells (left panel) and ONS76 cells (right panel) were either untreated (−) or treated with 2.5 μM PHA665752 (+) for 12,
24, 36, or 48 hours. Cell lysates were harvested, quantified, and analyzed by Western blot analysis with anti–caspase-3 antibody that will
detect the higher–molecular weight intact protein (single arrowhead) and the apoptotic cleaved product (double arrowhead). Jurkat cells
either untreated or treated with cytochrome c serve as positive and negative control lysates for caspase-3 cleavage.
